Congressional Report: FDA Broke Own Protocols in Approving Biogen Alzheimer's Drug

The FDA failed to adhere to its own guidance and internal practices during the approval process for Biogen's Alzheimer's drug Aduhelm, which was 'rife with irregularities,' a congressional report showed on Thursday.
Reuters Health Information

source https://www.medscape.com/viewarticle/986319?src=rss

Comments

Popular posts from this blog

DC’s Harllee Harper Is Using Public Health Tools to Prevent Gun Violence. Will It Work?